Compare CURV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURV | CRBU |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 203.9M |
| IPO Year | 2021 | 2021 |
| Metric | CURV | CRBU |
|---|---|---|
| Price | $1.12 | $1.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $1.59 | ★ $9.33 |
| AVG Volume (30 Days) | 406.5K | ★ 1.3M |
| Earning Date | 12-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,039,486,000.00 | $9,295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.08 | $0.66 |
| 52 Week High | $7.19 | $3.54 |
| Indicator | CURV | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 45.15 |
| Support Level | $1.08 | $1.75 |
| Resistance Level | $1.46 | $1.97 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 10.67 | 66.20 |
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.